Corporate Information

Stemrim History
Oct. 2006 Established a company aiming to develop new drugs based on the discovery of bone marrow multi-potent stem cell mobilization factors identified by Professor Katsuto Tamai of the Graduate School of Medicine, Osaka University.
Apr. 2007 Started collaborative research with Osaka University. We have since continued to create intellectual property from the results of research, obtaining 78 patents as of the present. (Other 43 patent applications are pending.)
Oct. 2008 Won a research grant from Japan Science & Technology Agency (JST), Industry-Academic Collaborative Seed Innovation Program.
Dec. 2009 Won a research grant from JST, “A-STEP (Adaptable and Seamless Technology Transfer Program through Target-driven R&D)”
Apr. 2010 Transferred our head office to Saito Bio Incubator (Ibaraki City, Osaka Prefecture) and set up a laboratory there.
Concluded a collaborative research contract with Shionogi & Co., Ltd. for research into bone marrow-derived stem cell mobilizing factor.
Nov. 2011 Won a research grant from JST, “A-STEP (Adaptable and Seamless Technology Transfer Program through Target-driven R&D)”
June 2012 Opened Kobe Lab in Port Island, Kobe. Expanded the capacity to perform drug efficacy tests using disease model animals.
July 2013 Expanded the laboratory in Saito Bio Incubator, expanded animal experiment facilities and absorbed the function of Kobe Lab.
Dec. 2013 "Won a research grant from JST, “A-STEP (Adaptable and Seamless Technology Transfer Program through Target-driven R&D)”.
Supported doctor-initiated clinical trials in Osaka University, in collaboration with an early and exploratory clinical trial facilities development project by The Japanese Ministry of Health, Labor and Welfare."
Apr. 2014 Adopted as a joint research project of The Center of Medical Innovation and Translational Research (CoMIT), Osaka University Graduate School of Medicine.
May 2014 Won a research grant from the New Energy and Industrial Technology Development Organization (NEDO), Innovation Commercialization Venture Support Project.
Nov. 2014 Concluded a licensing contract with Shionogi and Co. for HMGB1.
Aug. 2015 An investigator-initiated trial of HMGB1 started at National University Corporation Osaka University.
Dec. 2017 An investigator-initiated trial (phase II) of HMGB1 peptides in patients with epidermolysis bullosa started.
July 2018 Changed our company name to StemRIM.
Apr. 2019 A corporate trial (phase II) of HMGB1 peptides in patients with cerebral infarction started.